CardieX Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

CardieX şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-24.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-24.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CDX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CDX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

CardieX Piyasaya Karşı Temettü Getirisi

CDX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CDX)	n/a
Pazarın Alt %25'i (AU)	2.6%
Pazarın En İyi %25'i (AU)	6.0%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (CDX) (3 yıla kadar)	n/a

Önemli Temettü: CDX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CDX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CDX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CDX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

CardieX Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New minor risk - Share price stability

CardieX Limited, Annual General Meeting, Nov 29, 2024

Full year 2024 earnings released: AU$0.034 loss per share (vs AU$0.14 loss in FY 2023)

CardieX (ASX:CDX) Is Carrying A Fair Bit Of Debt

Full year 2024 earnings released: AU$0.038 loss per share (vs AU$0.14 loss in FY 2023)

New major risk - Market cap size

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.059 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?

Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin